antipsychotics
-
antipsychotics, claims data, drug shortages, Drugs, FDA, first-generation antipsychotics, haloperidol, perphenazine, pharmacy, Psychiatry, psychosis, psychotic disorders, schizophreniaAntipsychotic Shortages Caused Drug Switching: 95,968-Patient Claims Study (2026)
First-generation antipsychotic (FGA) shortages are not just pharmacy annoyances; they force medication…
-
antipsychotics, cardiovascular risk, case-control study, cognition, Dementia, Diabetes, Drugs, head injury, integrated care, metabolic syndrome, modifiable risk factors, Neurodegenerative Diseases, Psychiatry, Psychology, psychosis, schizophrenia, smokingSchizophrenia Dementia Risk: Diabetes, Head Injury, Substance Use
Patients with schizophrenia have substantially elevated dementia risk compared to the general…
-
antipsychotics, AUROC, clinical decision support, clozapine, Drugs, electronic health records, InterSePT, machine learning, natural language processing, Psychiatry, psychosis, schizophrenia, treatment-resistant schizophrenia, xgboostMachine Learning Predicts Clozapine Initiation in Schizophrenia
Clozapine is the only medication with proven efficacy for treatment-resistant schizophrenia, yet…
-
5-HT7, acute psychosis, antipsychotics, d2 receptor, Drugs, JEWEL trial, lurasidone, negative symptoms, Neurotransmitters, PANSS, positive symptoms, Psychiatry, psychosis, schizophreniaLurasidone Improves Positive Symptoms of Schizophrenia More Than Negative
Lurasidone is approved for schizophrenia and bipolar depression on the strength of…
-
18F-DOPA PET, antipsychotics, Brain, caudate, dopamine, dopamine hypothesis, Drugs, longitudinal, neuroimaging, neuroscience, Neurotransmitters, psychosis, relapse, remission, schizophrenia, striatumStriatal Dopamine Drops From Psychosis to Schizophrenia Remission
The dopamine hypothesis of schizophrenia is the field’s longest-running mechanistic story, and…
-
agitation, antipsychotics, atypical antipsychotics, cardiovascular disease, CPRD, Dementia, Drugs, FDA black-box warning, matched cohort study, Neurodegenerative Diseases, older adults, Psychiatry, risperidone, side effects, strokeRisperidone Stroke Risk in Dementia: HR 1.28 Across CVD Subgroups
The risperidone-stroke link in dementia is one of the longest-running safety signals…
-
accelerated aging, advanced aging, aging, antipsychotics, brain age, Dementia, epigenetic clock, mortality, neuroscience, psychosis, schizophrenia, systematic review, telomere lengthSchizophrenia and Accelerated Aging: What The Latest Research Suggests In 2026
Research Highlights People with schizophrenia die 15–20 years earlier on average (SMR…
-
antipsychotics, British Journal of Psychiatry, cardiometabolic risk, causal inference, comorbidities, comorbidity, early intervention, Editor Eimear Foley, first episode psychosis, haloperidol, mediation analysis, metabolic health, mortality gap, obesity, olanzapine, personalised medicine, physical health inequalities, precision psychiatry, prediction modelling, psychosis, randomised controlled trial, schizophrenia, side effects, topical, weight gainCan we predict and prevent weight gain in early psychosis?
On average, people with psychosis die 15 years earlier than the general…
-
#UCLJournalClub, antipsychotic discontinuation, antipsychotics, dose reduction, Editor Dafni Katsampa, first episode psychosis, JAMA Psychiatry, NICE guidelines, psychosis, randomised controlled trial, schizophrenia, secondary care, topical, UCL Division of PsychiatryStop, reduce or stay on antipsychotics after first-episode psychosis?
Recovery from first-episode psychosis (FEP) often brings a sense of relief, but…
-
antipsychotics, atypical antipsychotics, bipolar disorder, child and adolescent, Editor Simon Bradstreet, metformin, obesity, randomised controlled trial, second generation antipsychotics, side effects, The Lancet Psychiatry, topical, weight, weight gain, Young people, youth mental healthMetformin reduces weight gain in young people taking antipsychotics
In the past decade, accumulating evidence has shown the efficacy of second-generation…
